Welcome to our dedicated page for Freenome SEC filings (Ticker: PCSC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Freenome's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Freenome's regulatory disclosures and financial reporting.
Freenome, Inc. has received FDA approval for SimpleScreen™ CRC, a blood-based screening test for colorectal cancer in adults aged 45 and older at average risk. The test analyzes cell-free DNA using AI/ML technology and was validated in the PREEMPT CRC study of more than 48,000 participants at over 200 sites.
In a prespecified analysis, SimpleScreen CRC showed 81.1% sensitivity for colorectal cancer, 13.7% sensitivity for advanced precancerous lesions (30.7% with high-grade dysplasia), and 90.4% specificity for advanced colorectal neoplasia. With approval, the test meets Medicare coverage criteria and is expected to be named in American Cancer Society guidelines, supporting broader access.
Under an August 2025 commercial agreement, Abbott will exclusively commercialize SimpleScreen CRC in the U.S. and will pay Freenome a $100 million milestone tied to this FDA approval. The product is the first commercial milestone in Freenome’s Personalized Cancer Detection strategy and will be integrated into its broader SimpleScreen portfolio and multiomics-based pipeline.
Freenome, Inc. reported that former director Kenneth Song converted 30,000 Class B Ordinary Shares into 30,000 shares of Common Stock on July 20, 2026, in connection with its business combination with Old Freenome. After these conversions, he holds 30,000 Common shares and no remaining Class B shares.
Freenome, Inc., the Delaware successor to Perceptive Capital Solutions Corp. (PCSC), filed a post-effective amendment to its Form S-4 registration statement under Rule 414(d) to reflect its Domestication, name change and completion of a business combination with Freenome Holdings, Inc. PCSC continued out of the Cayman Islands and domesticated into Delaware under Section 388 of the DGCL, changing its name to Freenome, Inc.
In the Domestication, PCSC redeemed public Class A shares validly submitted for redemption, converted each Class B share into a Class A share on a one-for-one basis, and then converted each outstanding Class A share into one share of New Freenome common stock. Trading of New Freenome common stock on Nasdaq began on July 21, 2026 under ticker “FRNM”. The amendment also describes New Freenome’s expanded director and officer indemnification arrangements under Delaware law and confirms that no additional securities are being registered and no further registration fee is required.
Freenome, Inc., formerly Perceptive Capital Solutions Corp., completed its business combination and domestication on July 20, 2026, ceasing to be a shell company and becoming the public parent of Freenome Holdings, Inc. Its common stock now trades on the Nasdaq Capital Market under the symbol FRNM.
New Freenome received gross proceeds of approximately $310.3 million in connection with the transaction, including $70.3 million from PCSC’s trust account and $240.0 million from a PIPE in which investors purchased 24,000,000 shares at $10.00 per share. Holders of 1,392,723 Class A shares redeemed at about $10.82 per share for roughly $15.1 million. Pro forma securities outstanding include 68,065,429 shares issued to former Freenome stockholders, 6,478,269 to PCSC shareholders, 2,442,500 to the sponsor and initial shareholders, plus options on 8,272,601 shares and RSUs on 4,034,512 shares. Shares of New Freenome common stock issued and outstanding totaled 107,446,814 as of the Closing Date.
An Investor Rights Agreement and PIPE subscription agreements provide registration rights covering about 65,440,613 shares, representing approximately 60.9% of outstanding common stock, and key holders are subject to a six‑month lock‑up. New Freenome adopted a 2026 Equity Incentive Plan initially reserving 14,773,227 shares (with an automatic 5% annual increase feature) and a 2026 Employee Stock Purchase Plan initially reserving 2,462,204 shares with capped annual increases. A new Executive Severance Plan, updated charter and bylaws, a staggered seven‑member board, and auditor transition to EY were also put in place. Major holders include Roche at 17.4%, RA Capital at 14.3%, Perceptive Life Sciences Master Fund at 12.4%, Andreessen Horowitz at 5.2%, and directors and officers as a group at 4.7%.
Perceptive Capital Solutions Holdings, a former 10% owner of Freenome, Inc., reported the conversion of 2,066,250 Class B Ordinary Shares into the same number of shares of Common Stock on July 20, 2026 in connection with Freenome's business combination with Old Freenome. Following the one-for-one conversions, the reporting person holds 2,352,500 shares of Common Stock directly, and its two directors, Adam Stone and Michael Altman, share voting and investment discretion over these securities. The transactions were not executed under a Rule 10b5-1 trading plan.
Perceptive Advisors LLC, together with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., reports beneficial ownership of Freenome, Inc. Common Stock on a Schedule 13G. The Master Fund directly holds 10,871,847 shares of Common Stock, and each Reporting Person may be deemed to beneficially own these shares.
The ownership represents 10.1% of Freenome’s Common Stock, based on 107,446,814 shares outstanding as of July 20, 2026 as reported by the issuer. Each Reporting Person has 0 shares with sole voting or dispositive power and 10,871,847 shares with shared voting and shared dispositive power.
Freenome, Inc. reported that Perceptive Life Sciences Master Fund Ltd. acquired 5,500,000 shares of Common Stock on July 20, 2026 at $10.00 per share, in a grant/award-type acquisition. Following this transaction, the Master Fund’s reported Common Stock holdings total 10,871,847 shares. The securities are directly held by the Master Fund; Perceptive Advisors LLC, as investment manager, and Joseph Edelman, as managing member of the Advisor, report indirect pecuniary interests and each disclaims beneficial ownership beyond that. The Rule 10b5-1 trading plan checkbox was not marked for this transaction.
Freenome, Inc. reports that Perceptive Life Sciences Master Fund Ltd, Perceptive Advisors LLC and Joseph Edelman have filed an initial statement of beneficial ownership as 10% owners. The common stock reported corresponds to Legacy Freenome Series B, C, D and F preferred shares on an as-converted basis in connection with a business combination between Freenome Holdings, Inc. and Perceptive Capital Solutions Corp. under a Business Combination Agreement dated December 5, 2025. Perceptive Advisors and Mr. Edelman disclaim beneficial ownership beyond their indirect pecuniary interest.
Freenome, Inc. reported that former director Mark C. McKenna converted 30,000 Class B Ordinary Shares into 30,000 shares of Common Stock on July 20, 2026, in connection with the closing of its Business Combination under the Business Combination Agreement dated December 5, 2025 and amended July 20, 2026.
Freenome, Inc. reported that Perceptive Capital Solutions Holdings (the Sponsor) converted 2,066,250 Class B Ordinary Shares into the same number of shares of Common Stock on July 20, 2026 in connection with the closing of its business combination with Freenome Holdings, Inc.
The securities are held indirectly by the Sponsor, whose board, including Adam Stone and Michael Altman, has voting and investment discretion, resulting in 2,352,500 shares of Common Stock held indirectly after the conversion.